Highlights Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Market Closed - Bombay S.E. Other stock markets 03:30:58 05/07/2024 pm IST			5-day change	1st Jan Change
1,011 ^INR	-1.90%		-1.31%	+11.04%

12/06	Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	MT
11/06	Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	12/06	MT
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	11/06	CI
Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit	22/05	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04	MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03	MT
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03	RE
Eris Lifesciences Limited agreed to acquire additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel for INR 2.4 billion.	14/03	CI
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14/03	CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16/02	MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15/02	CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13/02	CI
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13/02	CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08/02	RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10/11	CI
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08/11	CI
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	08/11	CI
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/23/07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Highlights

Filters